A few days but but what a cracker!!! Just what i had hoped-for. Strong growth across rev (up 60%!), EBITDA, EBIT and NPAT grew by 52.2%. Despite massive increase in CAPEX, strong AUD, rising labour costs, margins have effectively been maintained at over 23%. Operating cashflow reduced due to capex but CR ensured low debt at only 12.7%. Also confirmation the Brandrill aquisition (which i urger ASL to make 2 yrs ago) has proved a great success.
The important thing is that ASL is able to increase BOTH rig utilisation rate and profits on each drill rig contracted out. This is a multiple effect and should not be under-estimated.
The only downside (in short term) is that due to CR the EPS has not risen as fast as other metrics. EPS up 14.4% to 23.7c. Final div up only half-cent to 6.5c ffr.
But oulook is positive. Company forecast rev to rise 20% and hit 1 Billion mark. I expect no more CR and as new acquisitions rapidly produce income (esp mineral analytical labs) that EPS will rise 20% in FY12. Am expecting total divs in FY12 of 14.5c (6.5+8). Assuming I'm right what PE does one apply to a company able to grow earnings at this rate?
- Forums
- ASX - By Stock
- PRN
- results for fy12
results for fy12, page-6
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PRN (ASX) to my watchlist
(20min delay)
|
|||||
Last
99.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $930.9M |
Open | High | Low | Value | Volume |
99.0¢ | $1.00 | 99.0¢ | $751.1K | 755.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
42 | 113191 | 99.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
99.5¢ | 51950 | 44 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
41 | 112651 | 0.990 |
19 | 80398 | 0.985 |
16 | 95084 | 0.980 |
10 | 156540 | 0.975 |
5 | 82598 | 0.970 |
Price($) | Vol. | No. |
---|---|---|
0.995 | 44183 | 44 |
1.000 | 133486 | 23 |
1.005 | 31536 | 10 |
1.010 | 121140 | 13 |
1.015 | 34307 | 6 |
Last trade - 14.53pm 15/07/2024 (20 minute delay) ? |
Featured News
PRN (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online